Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 200 versus MD 76R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 200 versus MD 76R.
IOPAMIDOL-200 vs MD-76R
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a nonionic iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast. It does not have a pharmacological effect but provides radiographic opacity.
MD-76R is a radiopaque contrast agent that contains iodine, which attenuates X-rays, thereby enhancing the contrast of blood vessels and tissues during radiographic procedures. It functions by increasing the absorption of X-rays in areas where it is present, allowing for visualization of vascular structures and organ perfusion.
Intravascular: 50-150 mL (75-225 mg iodine/kg) IV; frequency depends on procedure, usually single dose. Intrathecal: 5-15 mL (200 mg iodine/mL) injected into subarachnoid space.
2–4 mL/kg intravenously, maximum 150 mL per procedure.
None Documented
None Documented
Terminal half-life: 2 hours (normal renal function); prolonged to 8-48 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life 1-2 hours; prolonged in renal impairment.
Renal: >95% unchanged via glomerular filtration within 24 hours; biliary/fecal: <1%.
Primarily renal; 95% eliminated unchanged in urine within 24 hours; <1% fecal.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent